John Silke Selected Research

birinapant

10/2020	Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.
10/2020	Targeting triple-negative breast cancers with the Smac-mimetic birinapant.
1/2020	Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo.
1/2019	Antagonism of IAPs Enhances CAR T-cell Efficacy.
10/2017	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.
2/2016	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.
1/2016	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
5/2015	Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.
5/2014	Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Silke Research Topics

Disease

33	Neoplasms (Cancer) 12/2021 - 06/2004
28	Inflammation (Inflammations) 01/2022 - 10/2000
11	Necrosis 10/2018 - 10/2000
10	Infections 01/2020 - 01/2010
5	Dermatitis 01/2022 - 03/2011
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2020 - 01/2016
3	Carcinogenesis 09/2021 - 11/2008
3	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 05/2014
2	Leukemia 10/2020 - 12/2008
2	Lymphadenopathy 01/2020 - 01/2016
2	Hyperplasia 12/2015 - 10/2002
2	Wounds and Injuries (Trauma) 09/2015 - 07/2006
2	Multiple Myeloma 04/2011 - 03/2008
2	Brain Injuries (Brain Injury) 11/2008 - 07/2006
1	COVID-19 01/2022
1	Airway Remodeling 01/2022
1	Emphysema 01/2022
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Stomach Neoplasms (Stomach Cancer) 11/2021
1	Atrophy 10/2021
1	Thrombosis (Thrombus) 01/2021
1	Triple Negative Breast Neoplasms 10/2020
1	Breast Neoplasms (Breast Cancer) 10/2020
1	Fever (Fevers) 01/2020
1	Malaria 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Genomic Instability 01/2019
1	Chromosomal Instability (Chromosome Stability) 01/2019
1	Anemia 01/2019
1	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2018
1	Stevens-Johnson Syndrome (Lyell's Syndrome) 11/2017
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2017
1	Bacterial Infections (Bacterial Infection) 01/2017
1	Brain Diseases (Brain Disorder) 01/2017
1	2 X-Linked Lymphoproliferative Syndrome 01/2017
1	Carcinoma (Carcinomatosis) 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Cachexia 09/2015
1	Weight Loss (Weight Reduction) 09/2015

Drug/Important Bio-Agent (IBA)

27	Proteins (Proteins, Gene)FDA Link 11/2020 - 03/2008
13	Phosphotransferases (Kinase)IBA 01/2021 - 01/2013
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2021 - 11/2007
10	CytokinesIBA 12/2021 - 04/2014
10	CaspasesIBA 01/2020 - 12/2008
9	birinapantIBA 10/2020 - 05/2014
7	Caspase 8 (Caspase-8)IBA 01/2022 - 01/2009
7	Inhibitor of Apoptosis ProteinsIBA 01/2020 - 04/2014
5	sharpinIBA 01/2022 - 03/2011
5	UbiquitinIBA 10/2021 - 11/2008
5	Type I Tumor Necrosis Factor ReceptorsIBA 01/2018 - 08/2013
4	Death Domain ReceptorsIBA 10/2020 - 09/2013
4	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 04/2014 - 03/2011
3	Protein Kinases (Protein Kinase)IBA 01/2019 - 03/2015
3	PerforinIBA 01/2019 - 10/2017
3	AntigensIBA 01/2018 - 05/2015
3	InterferonsIBA 01/2018 - 01/2017
3	TNF Receptor-Associated Factor 2 (TRAF2)IBA 01/2017 - 04/2011
3	Ligases (Synthetase)IBA 06/2012 - 05/2011
3	NF-kappa B (NF-kB)IBA 01/2010 - 11/2007
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 05/2015
2	Surface Antigens (Surface Antigen)IBA 01/2020 - 05/2015
2	Granzymes (Granzyme)IBA 10/2017 - 10/2000
2	Cysteine Proteases (Cysteine Protease)IBA 02/2017 - 01/2017
2	sphingosine kinaseIBA 01/2017 - 12/2015
2	Type III Secretion SystemsIBA 01/2017 - 09/2013
2	AntibodiesIBA 09/2015 - 03/2008
2	Interleukin-33IBA 07/2015 - 05/2014
2	Pharmaceutical PreparationsIBA 05/2015 - 01/2015
2	Carrier Proteins (Binding Protein)IBA 11/2008 - 07/2006
2	Caspase 9IBA 06/2004 - 10/2002
1	SmokeIBA 01/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022
1	B7-H1 AntigenIBA 11/2021
1	Transcription Factors (Transcription Factor)IBA 09/2021
1	Estrogen ReceptorsIBA 10/2020
1	ChemokinesIBA 01/2020
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2020
1	Antimalarials (Antimalarial Agents)IBA 01/2020
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2019
1	Fas Ligand Protein (Fas Ligand)IBA 01/2018
1	DioxygenasesIBA 01/2018
1	Cysteamine (Mercaptamine)FDA Link 01/2018
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 01/2018
1	EkoIBA 11/2017
1	LipopolysaccharidesIBA 01/2017
1	Poly I-CIBA 01/2017
1	LCL161IBA 01/2017
1	3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acidIBA 01/2016
1	InflammasomesIBA 01/2016
1	Cytokine TWEAKIBA 09/2015
1	TWEAK ReceptorIBA 09/2015
1	InterleukinsIBA 07/2015
1	Interleukin-18 (Interleukin 18)IBA 07/2015

Therapy/Procedure

5	Therapeutics 01/2019 - 05/2015
4	Immunotherapy 12/2021 - 01/2018
2	Drug Therapy (Chemotherapy) 01/2020 - 01/2016
1	Braces 01/2020